Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25476691 | 0.98 | CASP2 (0.66) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL18704712 | 0.92 | CASP2 (0.57) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL12555034 | 0.92 | CASP2 (0.55) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL12554739 | 0.92 | CASP2 (0.55) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL9518701 | 0.87 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL9502450 | 0.87 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL1146790 | 0.87 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL14984424 | 0.86 | CASP2 (0.47) | CASP2NAAAFAAHDNM1 | |
| SCHEMBL16384356 | 0.86 | CASP2 (0.65) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL12360830 | 0.85 | FAAH (0.62) | CASP2NAAAFAAHDNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | claimed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | claimed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | claimed |
| US-20210318340-A1 | MOLECULAR HOPPER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | KRT18, TYR, MC1R | CASP2 2590/4885NAAA 1707/4885FAAH 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.